

THURSDAY FEBRUARY 4

Physicians Programme

- 13:45 – 13:55** **Opening Ceremony**
EBMT President Prof. Nicolaus Kroeger & EHA President Prof. John Gribben
- 14:00 – 15:00** **Session I, Clinical Indications 1**
Chairs: Nicolaus Kroeger (DE) & John Gribben (UK)
- CAR T-cells for adult ALL Arnon Nagler (IL)
 - CAR T-cell Therapy for MM: Current Concepts
– Perspective for the Future Hermann Einsele (DE)
 - Factors associated with outcomes of CD19
CAR T-cell therapy Cameron Turtle (US)
 - Q&A
- 15:00 – 15:30** **Break**
- 15:30 – 16:30** **Session II, Clinical Indications 2**
Chairs: Claire Roddie (UK) & Chiara Bonini (IT)
- CAR T-cell therapy in large B-cell lymphomas:
clinical indications Paolo Corradini (IT)
 - CAR-T in Acute Myeloid Leukemia Gerhard Ehninger (DE)
 - Mantle Cell Lymphoma Roch Houot (FR)
 - Q&A
- 16:30 – 17:00** **Break**
- 17:00 – 17:45** **Keynote Lecture**
Chairs: Hermann Einsele (DE) & Christian Chabannon (FR)
- Strategies to improve efficacy of CAR T-cells in
hematologic malignancies and solid tumors Stanley R. Riddell (US)
 - Q&A
- 17:50 – 18:20** **Best Abstracts and Flash Talks I**
- Universal chimeric antigen receptor
(CAR)-engineered T cells from induced pluripotent stem cells Alexandros Nianias (NL)
 - Antibiotic-induced Microbiome Injury in CAR T-cell
Patients correlates with Toxicity and Outcome Viktoria Blumenberg (DE)
 - ARI-0001 CART19 cells in relapsed B-ALL with
Isolated Extramedullary Disease Valentin Ortiz-Maldonado (SP)
 - CD19 hypermethylation as an escape to CART-19 Michal Smida (CZ)
- 18:25 – 19:10** **Satellite Symposium by Janssen | A new chapter in the treatment of patients with relapsed / refractory multiple myeloma**
Chair: Maria Victoria Mateos (SP)
- Clinical advances with CAR-Ts and bispecifics
in relapsed/refractory multiple myeloma Adam Cohen (US)
 - A look into the future: possibilities for advanced
therapy medicinal products in the management of patients with multiple myeloma Maria Victoria Mateos (SP)
 - Pannel discussion and Q&A

FRIDAY FEBRUARY 5

Physicians Programme

09:00 – 09:45 Keynote Lecture

Chairs: Marion Subklewe (DE) & Ibrahim Yakoub-Agha (FR)

- Progression of CAR T trials in China Jianxiang Wang (CN)
- Q&A

09:45 – 10:00 Break

10:00 – 11:00 Session III - Optimizing CAR T-cell Therapy

Chairs: Hermann Einsele (DE) & Arnon Nagler (IL)

- Mechanisms behind CAR T-cells Marcela Maus (US)
- Virus-free CAR-T at the bench and in the clinic Michael Hudecek (DE)
- Tumor glycosylation: impact on CAR T-cell efficacy Monica Casucci (IT)
- Q&A

11:00 – 11:15 Break

11:15 – 12:15 Session IV - Pediatrics CAR T

Chairs: Tobias Feuchtinger (DE) & Annette Künkele (DE)

- The challenges of CAR T-cell therapy for paediatric B-ALL Sara Ghorashian (UK)
- Beyond CD19 CAR T cells for B-ALL Rebecca Gardner (US)
- From hematological malignancies to solid tumor treatment: the journey of CAR T therapy in the pediatric setting Concetta Quintarelli (IT)
- Q&A

12:20 – 12:50 Best Abstracts and Flash Talks II

- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML Martin Wermke (DE)
- CAR-Treg Therapy for Systemic Lupus Erythematosus Matteo Doglio (IT)
- JULIET: 40-month clinical update and biomarker analysis Paolo Corradini (IT)
- Sleeping Beauty engineered CAR T cells for B-ALL Chiara F. Magnani (IT)
- Characterisation and Clinical Outcomes of Different Bridging Strategies in patients receiving CD19CAR-T Therapy for Relapsed/Refractory B cell Lymphomas Maria A. V. Marzolini (UK)
- CAR-HEMATOTOX: a multivariate score to predict hematotoxicity after CAR T-cell therapy for relapsed/refractory B-cell lymphoma Kai Rejeski (DE)

13:00 – 13:45 Satellite Symposium by Kite and Gilead | Reaching new landmarks in survival with CAR T-cell therapy

Chair: Martin Dreyling (DE)

- CAR T-cell therapy in NHL: The story so far (4-year landmark) Anna Sureda (SP)
- Reshaping the treatment paradigm in R/R mantle cell lymphoma: Perspective on CAR T Martin Dreyling (DE)
- Patient case discussion Loïc Ysebaert (FR)
- Q&A

13:45 – 15:00 Break

14:15 – 14:45 Meet the Expert Session: Marcela Maus (US)

No registration required. Limited space available

15:00 – 15:45 Satellite Symposium by Bristol Myers Squibb | Practical aspects of CAR T-cell therapy

Chair: Ulrich Jaeger (AT)

- CAR T-cell therapy in the daily care of patients with B-cell malignancies Peter Borchmann (DE)
- Implementation of CAR T-cell therapy in MM: practical and patient-related aspects Maria Victoria Mateos (SP)
- Q&A

15:50 – 16:50 Session V - Interactive pros / cons: future application of CAR T-cells

Chairs: Hermann Einsele (DE) & Fabio Ciceri (IT)

-
- BiTE vs CART: pro BiTE Marion Subklewe (DE)
- BiTE vs CART: pro CART Catherine Thieblemont (FR)
- CAR vs BiTEs in multiple myeloma Sebastien Anguille (BE)
- Q&A

16:55 – 17:55 Session VI - CAR effector cells (non T-cells)

Chairs: Claire Roddie (UK) & Michael Hudecek (DE)

- Adoptive cell therapy with tumor-redirected iNKT cells Paolo Dellabona (IT)
- CARs NK Ulrike Koehl (DE)
- Allogeneic CAR Ts Reuben Benjamin (UK)
- Q&A

17:55 – 18:15 Break

18:15 – 19:00 Keynote Lecture

Chairs: Christian Chabannon (FR) & John Gribben (UK)

- Epigenetic landscaping of CAR T-cells - early insights Michel Sadelain (US)
- Q&A

19:05 – 19:50 IMI Project Workshop| How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!

Chairs: Michael Hudecek (DE) & Scott Wagers (BE)

Interactive panel discussion hosted by the imSAVAR and T2EVOLVE IMI projects

Michael Hudecek | Coordinator T2EVOLVE IMI Project

Ibtissam Marchiq, Project Leader Immuno-Oncology

Ulrike Koehl | Coordinator imSAVAR IMI Project

Jonathan Moggs| imSAVAR Industry Partner Coordinator

Stanley R. Riddell | Key Opinion Leader

FRIDAY FEBRUARY 5

Nurses Programme

10:00 – 10:05 **Introduction and welcome**
Erik Aerts (CH)

10:05 – 11:05 **Session I**
Chair: Erik Aerts (CH)

- Establishing a multiprofessional CAR T Cell Communication Board
- Immune Effector Cells in Solid Tumours
- Where are we now and where are we going with paediatric CART
- Q&A

Martina Spalt (AT)

Jessica Ritchie (UK)
Francesco Ceppi (CH)

11:05 – 11:15 **Break**

11:15 – 12:35 **Session II**
Chair: John Murray (UK)

- Post Infusion blood tests, what are they all for?
- Does it work in other haematological diseases?
- What centre requirements are needed for JACIE
- GoCART
- Q&A

Amit Patel (UK)
Reuben Benjamin (UK)
Rob Wosley (UK)
Sofie Terwel (NL)

12:35 – 15:45 **Break**

15:45 – 16:35 **Session III**
Chair: Mairead Ni Chonghaile (IE)

- Spotlight on the Lymphoma Patient Experience
- Q&A
- Group Discussion – Ethics of CAR-T
 - Ruth Ting (UK)
 - Lorna Warwick (CA)
 - Erik Aerts (CH)
 - Martina Spalt (AT)

Lorna Warwick (CA)

16:35 – 17:00 **Break**

17:00 – 18:00 **Session IV**
Chair: Michelle Kenyon (UK)

- Basic nursing care a training program
- Case study
- Survivorship Considerations After CAR T-Cell Therapy
- Q&A

Ruth Clout (UK)
Rose Ellard (UK)
Nicole Crisp (CA)

18:00 – 18:10 **Closing remarks**
Michelle Kenyon (UK)

SATURDAY FEBRUARY 6

Physicians Programme

09:30 – 10:30 **Session VII - side effects - recognition and treatment including novel insights into pathophysiology**

Chairs: Monica Casucci (IT) & Marion Subklewe (DE)

- Cytopenias post-CAR T-cell therapy Ibrahim Yakoub-Agha (FR)
- CRS, ICANS and the steroids to prevent it Max Topp (DE)
- Infections Complications of CAR T-cell Therapies: A Paradigm on the move Joshua Hill (US)
- Q&A

09:30 – 10:30 **Session VIII: CAR T regulatory issue + reimbursements (in country and across borders)**

Chairs: Michael Hudecek (DE) & Jurgen Kuball (NL)

- Academic delivery through a national service Alvaro Urbano-Ispizua (SP)
- CAR T Access: Importance of Reimbursement and Manufacturing Networks Emanuele Ostuni (CH)
- Involving patients to solve the hurdles across the HTA process Stephen Scowcroft (UK)
- Q&A

09:30 – 10:30 **Session IX: Data Management: real world data / LTFU / data collection**

Chairs: Mohamad Mohty (FR) & Natacha Bolaños (SP)

- Results of treatment with tisacel and axicel in real world conditions; report from the CIBMTR / CIDR Marcelo Pasquini (US)
- Defining conditions for shared access to data collected in a global repository for EU CAR T-cells treated patients Sofie Terwel (NL)
- CAR T-cells: the experience of patients and carers Guy Bouguet (FR)
- Q&A

10:30 – 11:00 **Break**

11:00 – 12:00

Session X - Academic production

Chairs: Stephan Mielke (SE) & Marion Subklewe (DE)

- Overcoming Cell Manufacturing Challenges in the Academic setting Isabelle Riviere (US)
- Why regulatory and commercial aspects should be improved for the successful ACT academic clinical trials Manel Juan (SP)
- Targeting SLAMF7 in Multiple Myeloma Halvard Böning (DE)
- Q&A

11:00 – 12:00

Session XI - Clinical challenges in CART

Chairs: Claire Roddie (UK) & Max Topp (DE)

- Inclusion criteria Catherine Thieblemont (FR)
- Infectious complications in patients treated with CAR T-cells Miguel Angel Perales (US)
- Factors Associated with Outcomes of Repeat CD19-targeted CAR T-cell infusions for Refractory B cell Malignancies Jordan Gauthier (US)
- Q&A

11:00 – 12:00

Session XII - EU grants and projects

Chairs: Christine Chomienne (FR) & Michael Hudecek (DE)

- EN-ACTI²NG: from TCRs to CARs and back Hisse M. van Santen (SP)
Ashwathi Menon (SP)
Tassilo Wachsmann (NL)
Lukas Velas (AT)
- CARAMBA & EURE-CART H2020 projects Michael Hudecek (DE)
- imSAVAR & T2EVOLVE IMI projects Ulrike Koehl (DE)
- Partnering with patient organisations in H2020 projects such as CARAMBA Ananda Plate (DE)
- Q&A

12:00 – 12:30

Break

12:30 – 13:15

Keynote Lecture

Chairs: Ibrahim Yakoub-Agha (FR) & Hermann Einsele (DE)

- Updates with Engineered T Cells Carl June (US)
- Q&A

13:20 – 13:35

Closing remarks

Meeting Chairs: Christian Chabannon, Hermann Einsele

EBMT President Prof. Nicolaus Kroeger & EHA President Prof. John Gribben